Sanofi and Merck may not be first to a Covid-19 vaccine, but they might be best
As the world pores over minute-by-minute updates from the frontrunners is the so-called race to develop a vaccine for Covid-19, experts warn not to count out a pair of experienced giants moving a bit more slowly.
As STAT’s Helen Branswell reports, Merck and Sanofi are currently behind the likes of Moderna, AstraZeneca, and partners Pfizer and BioNTech, but each has spent decades creating a global vaccine infrastructure its rivals can’t claim. Neither Moderna nor BioNTech has taken a vaccine all the way through to approval, for example, and each is working with technology that has never undergone an FDA review.
That could help Merck and Sanofi close the gap in the coming months, experts say. Faster competitors might be first to secure provisional approvals, but come 2021, when the world demands billions of vaccine doses, pharma’s established giants might seize the market.
Read more. (BROKEN LINKS)
As STAT’s Helen Branswell reports, Merck and Sanofi are currently behind the likes of Moderna, AstraZeneca, and partners Pfizer and BioNTech, but each has spent decades creating a global vaccine infrastructure its rivals can’t claim. Neither Moderna nor BioNTech has taken a vaccine all the way through to approval, for example, and each is working with technology that has never undergone an FDA review.
That could help Merck and Sanofi close the gap in the coming months, experts say. Faster competitors might be first to secure provisional approvals, but come 2021, when the world demands billions of vaccine doses, pharma’s established giants might seize the market.
Read more. (BROKEN LINKS)
.png)
No hay comentarios:
Publicar un comentario